Puma Biotechnology 향후 성장

Future 기준 점검 0/6

Puma Biotechnology 의 수익과 수익은 각각 연간 0.06% 및 14% 감소할 것으로 예상됩니다 while EPS는 연간 16.9% 만큼 쇠퇴할 것으로 예상됩니다.

핵심 정보

-14.0%

이익 성장률

-16.88%

EPS 성장률

Biotechs 이익 성장	22.6%
매출 성장률	-0.06%
향후 자기자본이익률	n/a
애널리스트 커버리지	Low
마지막 업데이트	07 Nov 2025

최근 향후 성장 업데이트

Recent updates

With EPS Growth And More, Puma Biotechnology (NASDAQ:PBYI) Makes An Interesting Case

Dec 09

Puma Biotechnology's (NASDAQ:PBYI) Shareholders May Want To Dig Deeper Than Statutory Profit

Nov 13

Puma Biotechnology: Step By Step In Making A Transition

Nov 10

Puma Biotechnology, Inc. (NASDAQ:PBYI) Stock Catapults 26% Though Its Price And Business Still Lag The Market

Oct 18

Does Puma Biotechnology (NASDAQ:PBYI) Have A Healthy Balance Sheet?

Sep 11

Puma Biotechnology, Inc. (NASDAQ:PBYI) Stock Catapults 43% Though Its Price And Business Still Lag The Market

Aug 12

We Ran A Stock Scan For Earnings Growth And Puma Biotechnology (NASDAQ:PBYI) Passed With Ease

Aug 09

Puma Biotechnology, Inc. (NASDAQ:PBYI) Shares Fly 25% But Investors Aren't Buying For Growth

May 20

Puma Biotechnology: Initiating Hold Rating With Limited Near-Term Upside And Uncertain Pipeline Potential

Apr 11

Puma Biotechnology, Inc. (NASDAQ:PBYI) Held Back By Insufficient Growth Even After Shares Climb 26%

Mar 10

Alisertib Trials And International NERLYNX Approvals Will Expand Market, But Single Product Dependence And Safety Concerns Could Limit Gains

Feb 09 Strategic collaborations and regulatory approvals in international markets are expected to drive global revenue growth and increase overall sales.

Insufficient Growth At Puma Biotechnology, Inc. (NASDAQ:PBYI) Hampers Share Price

Jan 14

Puma Biotechnology: Continuing To Push Their Aurora Kinase Story Forward

Dec 16

Puma Biotechnology's (NASDAQ:PBYI) Performance Is Even Better Than Its Earnings Suggest

Nov 14

Is Puma Biotechnology (NASDAQ:PBYI) A Risky Investment?

Sep 07

Lacklustre Performance Is Driving Puma Biotechnology, Inc.'s (NASDAQ:PBYI) 26% Price Drop

Aug 15

The Market Doesn't Like What It Sees From Puma Biotechnology, Inc.'s (NASDAQ:PBYI) Earnings Yet As Shares Tumble 25%

Jun 07

Here's Why We Think Puma Biotechnology (NASDAQ:PBYI) Might Deserve Your Attention Today

Jun 05

We Like The Quality Of Puma Biotechnology's (NASDAQ:PBYI) Earnings

May 09

Puma Biotechnology: A Story In Flux Heading Into Mid-2024

May 05

Is There An Opportunity With Puma Biotechnology, Inc.'s (NASDAQ:PBYI) 46% Undervaluation?

Apr 10

There's Reason For Concern Over Puma Biotechnology, Inc.'s (NASDAQ:PBYI) Massive 31% Price Jump

Mar 01

이익 및 매출 성장 예측

NasdaqGS:PBYI - 애널리스트 향후 추정치 및 과거 재무 데이터 (USD Millions)
날짜	매출	이익	자유현금흐름	영업현금흐름	평균 애널리스트 수
12/31/2028	218	23	59	N/A	1
12/31/2027	219	28	62	N/A	1
12/31/2026	220	20	65	N/A	1
12/31/2025	222	28	68	N/A	1
9/30/2025	212	37	43	43	N/A
6/30/2025	238	48	44	44	N/A
3/31/2025	233	38	31	31	N/A
12/31/2024	230	30	39	39	N/A
9/30/2024	244	23	34	34	N/A
6/30/2024	219	9	33	33	N/A
3/31/2024	227	15	35	36	N/A
12/31/2023	236	22	14	27	N/A
9/30/2023	229	4	5	24	N/A
6/30/2023	230	-2	11	31	N/A
3/31/2023	235	5	-6	14	N/A
12/31/2022	228	0	-23	-16	N/A
9/30/2022	218	10	-29	-29	N/A
6/30/2022	207	-34	-36	-36	N/A
3/31/2022	201	-49	-22	-22	N/A
12/31/2021	253	-29	21	21	N/A
9/30/2021	250	-48	20	20	N/A
6/30/2021	255	-35	12	12	N/A
3/31/2021	272	-27	18	28	N/A
12/31/2020	225	-60	-9	1	N/A
9/30/2020	235	-56	-2	8	N/A
6/30/2020	241	-42	-11	-1	N/A
3/31/2020	224	-82	27	27	N/A
12/31/2019	272	-76	22	22	N/A
9/30/2019	280	-95	28	28	N/A
6/30/2019	287	-92	N/A	28	N/A
3/31/2019	284	-99	N/A	-34	N/A
12/31/2018	251	-114	N/A	-24	N/A
9/30/2018	202	-147	N/A	-67	N/A
6/30/2018	145	-210	N/A	-114	N/A
3/31/2018	94	-243	N/A	-143	N/A
12/31/2017	28	-292	N/A	-172	N/A
9/30/2017	6	-301	N/A	-178	N/A
6/30/2017	N/A	-289	N/A	-158	N/A
3/31/2017	N/A	-278	N/A	-143	N/A
12/31/2016	N/A	-276	N/A	-142	N/A
9/30/2016	N/A	-265	N/A	-134	N/A
6/30/2016	N/A	-260	N/A	-136	N/A
3/31/2016	N/A	-258	N/A	-139	N/A
12/31/2015	N/A	-239	N/A	-154	N/A
9/30/2015	N/A	-225	N/A	-140	N/A
6/30/2015	N/A	-200	N/A	-127	N/A

애널리스트 향후 성장 전망

수입 대 저축률: PBYI 의 수익은 향후 3년간 감소할 것으로 예상됩니다(연간 -14%).

수익 vs 시장: PBYI 의 수익은 향후 3년간 감소할 것으로 예상됩니다(연간 -14%).

고성장 수익: PBYI 의 수익은 향후 3년간 감소할 것으로 예상됩니다.

수익 대 시장: PBYI 의 수익은 향후 3년간 감소할 것으로 예상됩니다(연간 -0.06%).

고성장 매출: PBYI 의 수익은 향후 3년 동안 감소할 것으로 예상됩니다(연간 -0.06%).

주당순이익 성장 예측

향후 자기자본이익률

미래 ROE: PBYI의 자본 수익률이 3년 후 높을 것으로 예상되는지 판단하기에 데이터가 부족합니다.

성장 기업 찾아보기

기업 분석 및 재무 데이터 상태

데이터	최종 업데이트 (UTC 시간)
기업 분석	2026/01/26 15:05
종가	2026/01/26 00:00
수익	2025/09/30
연간 수익	2024/12/31

데이터 소스

당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.

패키지	데이터	기간	미국 소스 예시 ^*
기업 재무제표	10년	손익계산서 현금흐름표 대차대조표	SEC 양식 10-K SEC 양식 10-Q
분석가 컨센서스 추정치	+3년	재무 예측 분석가 목표주가	분석가 리서치 보고서 Blue Matrix
시장 가격	30년	주가 배당, 분할 및 기타 조치	ICE 시장 데이터 SEC 양식 S-1
지분 구조	10년	주요 주주 내부자 거래	SEC 양식 4 SEC 양식 13D
경영진	10년	리더십 팀 이사회	SEC 양식 10-K SEC 양식 DEF 14A
주요 개발	10년	회사 공시	SEC 양식 8-K

^* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.

별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.

분석 모델 및 스노우플레이크

이 보고서를 생성하는 데 사용된 분석 모델의 세부 정보는 당사의 Github 페이지에서 확인할 수 있으며, 보고서 활용 방법에 대한 가이드와 Youtube 튜토리얼도 제공합니다.

Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.

산업 및 섹터 지표

산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.

분석가 소스

Puma Biotechnology, Inc.는 14명의 분석가가 다루고 있습니다. 이 중 1명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.

분석가	기관
Huidong Wang	Barclays
Geoffrey Meacham	BofA Global Research
Yigal Nochomovitz	Citigroup Inc

Puma Biotechnology 향후 성장

Future 기준 점검 0/6

핵심 정보

최근 향후 성장 업데이트

Consensus EPS estimates increase by 11%

Puma Biotechnology, Inc. Provides Earnings Guidance for the Fourth Quarter 2025

Puma Biotechnology, Inc. Provides Earnings Guidance for the Third Quarter and Full Year 2025

Puma Biotechnology, Inc. Provides Earnings Guidance for the Second Quarter and Full Year 2025

Puma Biotechnology, Inc. Provides Earnings Guidance for the First Quarter and Full Year of 2025

Consensus EPS estimates increase by 16%

Recent updates

New minor risk - Share price stability

Founder notifies of intention to sell stock

With EPS Growth And More, Puma Biotechnology (NASDAQ:PBYI) Makes An Interesting Case

Independent Director recently sold US$97k worth of stock

Investor sentiment deteriorates as stock falls 18%

Independent Director notifies of intention to sell stock

Puma Biotechnology's (NASDAQ:PBYI) Shareholders May Want To Dig Deeper Than Statutory Profit

Consensus EPS estimates increase by 11%

Puma Biotechnology: Step By Step In Making A Transition

Third quarter 2025 earnings: EPS and revenues exceed analyst expectations

Puma Biotechnology, Inc. Provides Earnings Guidance for the Fourth Quarter 2025

Puma Biotechnology, Inc. to Report Q3, 2025 Results on Nov 06, 2025

Puma Biotechnology, Inc. (NASDAQ:PBYI) Stock Catapults 26% Though Its Price And Business Still Lag The Market

Does Puma Biotechnology (NASDAQ:PBYI) Have A Healthy Balance Sheet?

Investor sentiment improves as stock rises 18%

Puma Biotechnology, Inc. (NASDAQ:PBYI) Stock Catapults 43% Though Its Price And Business Still Lag The Market

New minor risk - Share price stability

Second quarter 2025 earnings: EPS exceeds analyst expectations

We Ran A Stock Scan For Earnings Growth And Puma Biotechnology (NASDAQ:PBYI) Passed With Ease

Puma Biotechnology, Inc. Provides Earnings Guidance for the Third Quarter and Full Year 2025

Puma Biotechnology, Inc. to Report Q2, 2025 Results on Aug 07, 2025

Founder notifies of intention to sell stock

Puma Biotechnology, Inc.(NasdaqGS:PBYI) dropped from Russell 3000 Growth Index

Puma Biotechnology, Inc. (NASDAQ:PBYI) Shares Fly 25% But Investors Aren't Buying For Growth

Investor sentiment improves as stock rises 16%

First quarter 2025 earnings: EPS and revenues exceed analyst expectations

Puma Biotechnology, Inc. Announces Termination of Jeff J. Ludwig as Chief Commercial Officer

Puma Biotechnology, Inc. Provides Earnings Guidance for the Second Quarter and Full Year 2025

Puma Biotechnology, Inc., Annual General Meeting, Jun 11, 2025

Puma Biotechnology: Initiating Hold Rating With Limited Near-Term Upside And Uncertain Pipeline Potential

Puma Biotechnology, Inc. (NASDAQ:PBYI) Held Back By Insufficient Growth Even After Shares Climb 26%

Investor sentiment improves as stock rises 21%

Full year 2024 earnings: EPS and revenues exceed analyst expectations

Puma Biotechnology, Inc. Provides Earnings Guidance for the First Quarter and Full Year of 2025

Puma Biotechnology, Inc. to Report Q4, 2024 Results on Feb 27, 2025

Alisertib Trials And International NERLYNX Approvals Will Expand Market, But Single Product Dependence And Safety Concerns Could Limit Gains

Insufficient Growth At Puma Biotechnology, Inc. (NASDAQ:PBYI) Hampers Share Price

Investor sentiment improves as stock rises 23%

Founder notifies of intention to sell stock

New minor risk - Share price stability

Puma Biotechnology's NERLYNX Included in NCCN Clinical Practice Guidelines for the Treatment of Cervical Cancer with a HER2 Mutation

Puma Biotechnology: Continuing To Push Their Aurora Kinase Story Forward

Puma Biotechnology Announces Initiation of ALISCA-Breast1 Phase II Trial of Alisertib in Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer

Investor sentiment deteriorates as stock falls 16%

Puma Biotechnology's (NASDAQ:PBYI) Performance Is Even Better Than Its Earnings Suggest

Consensus EPS estimates increase by 16%

Third quarter 2024 earnings: EPS and revenues exceed analyst expectations

Puma Biotechnology, Inc. Revises Earnings Guidance for the Full Year 2024

Puma Biotechnology, Inc. to Report Q3, 2024 Results on Nov 07, 2024

Is Puma Biotechnology (NASDAQ:PBYI) A Risky Investment?

Independent Director recently sold US$81k worth of stock

Lacklustre Performance Is Driving Puma Biotechnology, Inc.'s (NASDAQ:PBYI) 26% Price Drop

Investor sentiment deteriorates as stock falls 27%

Independent Director notifies of intention to sell stock

New minor risk - Share price stability

New major risk - Revenue and earnings growth

Puma Biotechnology, Inc. Provides Earning Guidance for the Third Quarter and Full Year of 2024

Second quarter 2024 earnings: EPS and revenues exceed analyst expectations

Insufficient new directors

Founder recently sold US$81k worth of stock

Founder notifies of intention to sell stock

Puma Biotechnology, Inc. to Report Q2, 2024 Results on Aug 01, 2024

Investor sentiment improves as stock rises 22%

Founder notifies of intention to sell stock

The Market Doesn't Like What It Sees From Puma Biotechnology, Inc.'s (NASDAQ:PBYI) Earnings Yet As Shares Tumble 25%

Here's Why We Think Puma Biotechnology (NASDAQ:PBYI) Might Deserve Your Attention Today

Puma Biotechnology, Inc. Announces Presentation of Findings from A Phase II Study of Alisertib in Endocrine-Resistant Metastatic Breast Cancer (Tbcrc 041)

Investor sentiment deteriorates as stock falls 20%

We Like The Quality Of Puma Biotechnology's (NASDAQ:PBYI) Earnings